PARP1 and neoplasm: The compound shows high efficacy in in-vitro tumor cell growth inhibition assays[14-16] and is particularly effective against human tumor xenografts in combination with taxol,[17] irinotecan[18] and, spectacularly so, in a triple combination with irinotecan and a PARP-1 inhibitor[19].